8-K: Alnylam Grants CEO Performance Equity Award Through 2029

Alnylam Pharmaceuticals' Board of Directors has granted CEO Yvonne Greenstreet a special performance-based equity award to incentivize future growth and leadership through 2029.

Summary

• Alnylam Pharmaceuticals, Inc. granted a special equity award to CEO Yvonne Greenstreet, M.D., M.B.A., effective March 2, 2026.
• The award is fully performance-based, contingent on significant stock price appreciation through December 31, 2029 (the Vesting Date).
• Target shares are 55,373 performance share units, with a face value of $18.0 million based on the March 2, 2026 closing price of $325.07.
• Vesting requires the highest average closing price of the common stock over a 30-consecutive-trading-day period in the six months prior to the Vesting Date to meet thresholds between $500 (50% vesting) and $800 (200% vesting).
• The $500 threshold represents an approximate 54% increase over the grant date closing price and exceeds the all-time high trading price as of the grant date.
• The award aims to retain and incentivize Dr. Greenstreet as the company pursues its new 'Alnylam 2030' aspirational goals.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, reflecting confidence in Alnylam's leadership and future growth trajectory, with incentives directly tied to significant shareholder value creation.

Positives

• CEO Yvonne Greenstreet has led Alnylam to nearly 100% stockholder return.
• The company successfully launched AMVUTTRA in multiple indications, including a landmark approval in 2025 for TTR cardiomyopathy.
• Alnylam has a robust clinical pipeline with over 25 programs in active development, including three recently initiated Phase 3 trials.
• The company met or exceeded all 'Alnylam P 5 x25' goals, achieving profitability in 2025.
• The performance-based award aligns the CEO's incentives directly with significant stockholder value creation.
• The award aims to ensure sustained leadership and stability as Alnylam embarks on its next phase of growth towards 'Alnylam 2030' goals.

Risks

• The Special Award will be forfeited in full if the Future Average Stock Price does not reach $500 during the Measurement Period, indicating a risk of non-vesting if stock price targets are not met.
• Voluntary termination or retirement by Dr. Greenstreet prior to the Vesting Date will result in forfeiture of the Special Award, posing a retention risk if she chooses to leave under those circumstances.

Future Outlook

The company is embarking on its next phase of growth, aiming to achieve a new set of five-year aspirational goals, 'Alnylam 2030.' The Special Award is designed to incentivize CEO Yvonne Greenstreet to drive significant stock price appreciation, with targets reflecting increases of approximately 54%, 85%, 115%, and 146% over the grant date closing price by December 31, 2029.

Management Comments

• "Leading Alnylam Through the Next Phase of Growth Under Dr. Greenstreet's leadership as Chief Executive Officer, Alnylam has produced stockholder return of nearly 100%, launched AMVUTTRA in multiple indications, including the landmark approval in 2025 for TTR cardiomyopathy, and developed a high-yielding clinical pipeline with over 25 programs in active clinical development, including three recently initiated Phase 3 clinical trials."
• "The Company also met or exceeded all of its announced 'Alnylam P 5 x25' goals for the five-year period ending in 2025, including achieving profitability in 2025."
• "The Board recognized the importance of Dr. Greenstreet to the Company's continued success, including the vital role she will play as the Company endeavors to achieve its new set of five-year aspirational goals, 'Alnylam 2030'."
• "The Board views the Special Award as a prudent tool to advance its objectives of retaining and incentivizing Dr. Greenstreet over the next several years and ensuring sustained leadership and stability as Alnylam embarks on its next phase of growth."

Industry Context

StockSavvy.ai notes that performance-based equity awards for top executives are a common strategy in the biotechnology and pharmaceutical sectors to align leadership incentives with long-term shareholder value creation, especially for companies with significant R&D pipelines and recent product launches like Alnylam. Such awards are crucial for retaining experienced leadership in a highly competitive industry where executive talent is key to navigating complex regulatory landscapes and bringing innovative therapies to market.

Comparison to Industry Standards

• The performance thresholds for Alnylam's CEO award, requiring stock price increases of approximately 54% to 146% over the grant date price by 2029, are aggressive but not uncommon for high-growth biotech companies. For instance, similar long-term incentive plans at companies like Moderna or BioNTech during their growth phases often included substantial stock price appreciation targets to reward successful drug development and commercialization.
• The structure, which includes a baseline threshold exceeding the all-time high, is a strong signal of the board's confidence in future growth, comparable to 'stretch goals' seen in compensation plans at leading tech or pharma firms aiming for market leadership.
• The inclusion of a forfeiture clause for voluntary termination is standard practice to ensure executive retention through the performance period, mirroring best practices in executive compensation across industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant value creation if stock price targets are met, as the CEO's incentives are directly aligned with share appreciation.
• Employees: Signals stability in top leadership, potentially fostering a positive work environment and clear strategic direction.
• Management: The CEO is highly incentivized to achieve ambitious growth targets, ensuring focused leadership.

Next Steps

• Alnylam will file a form of the award agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
• The company will continue to pursue its 'Alnylam 2030' aspirational goals.

Key Dates

Recommendation

The filing details a significant performance-based equity award to the CEO, reflecting strong confidence from the Board in her leadership and the company's future growth prospects, particularly towards the 'Alnylam 2030' goals. The aggressive stock price targets (approximately 54% to 146% appreciation) indicate high expectations for shareholder value creation. While this is a positive signal for long-term potential and management alignment, it is an executive compensation event rather than a direct operational or financial results announcement. Therefore, a 'hold' recommendation is appropriate for investors to observe the execution of the 'Alnylam 2030' strategy and the company's progress towards these ambitious stock price targets before making further investment decisions. The current valuation and broader market conditions would also need to be considered for a more definitive stance.

Keywords

Alnylam Pharmaceuticals, ALNY, Executive Compensation, Performance Share Units, CEO Award, Yvonne Greenstreet, Stock Incentive Plan, Corporate Governance, Biotechnology, Pharmaceuticals, Stock Price Appreciation, TTR Cardiomyopathy, AMVUTTRA, Alnylam 2030